Vascular Closure Devices Market

Vascular Closure Devices Market Outlook (2025 to 2035)

The global vascular closure devices market is expected to reach USD 2,065 million by 2035, up from USD 954.6 million in 2024. During the forecast period (2025-2035), the industry is projected to register a CAGR of 7.3%.

The rising demand for advanced diagnostic imaging systems, such as MRI and CT scanners, is accelerating the need for efficient cooling solutions to maintain equipment performance and prolong its longevity. Stringent regulatory standards for medical device safety, combined with the growing installation of hospital-grade electronics, are driving the adoption of high-precision cooling technologies.

Metric	Value
Industry Size (2025E)	USD 1,021 million
Industry Value (2035F)	USD 2,065 million
CAGR (2025 to 2035)	7.3%

What are the drivers of vascular closure devices market?

One of the fundamental growth boosters of the Vascular Closure Devices Market is the increasing demand for diagnostic imaging systems (like MRI, CT scanners, and PET/CT) across the globe. These computers require effective thermal management to ensure they remain functional, accurate, and last long in operation. With the rise in the size of radiology departments in Hospitals and the implementation of AI-assisted diagnostic systems, cooling is an essential requirement.

The increasing popularity of energy efficiency in healthcare buildings is stimulating the demand for intelligent and environmentally friendly cooling systems. Other initiatives supported by governments aimed at advancing healthcare facilities, particularly in emerging economies, also contribute to rapid market growth. The widespread adoption of high-power lasers and linear accelerators in cancer therapy has also heightened the need for efficient cooling technology.

The downsizing of medical equipment raises the thermal density of the devices, making internal cooling systems mandatory. These, along with the improvements in liquid cooling systems and heat exchangers, are transforming the vascular closure devices industry.

What are the regional trends of vascular closure devices market?

North America will remain the leader in the medical equipment cooling market due to its well-developed healthcare sector, high rate of equipment penetration, and significant investments in R&D. The presence of major medical device makers in the U.S. ensures that thermal management systems will continue to undergo extensive technological improvements.

Europe is next in line, aided by its ageing population, high per capita healthcare spend and strict regulatory standards that favor energy-efficient medical technologies. The trendsetters in the use of environmentally friendly cooling for diagnostic and therapeutic devices are countries such as Germany, France, and the United Kingdom.

The Asia Pacific is expected to be the fastest-growing region, driven by the rapid rate of hospital construction, the increasing utilization of diagnostic imaging procedures, and government healthcare reforms in China, India, and Southeast Asia. Partnerships between local participants and international producers are also facilitating market penetration.

Latin America and the Middle East & Africa regionally demonstrate moderate growth, which is limited by economic factors but assisted by the modernization of healthcare facilities, mainly in Brazil, South Africa, and the Gulf Cooperation Council (GCC) states.

What are the challenges and restraining factors of vascular closure devices market?

One of the inhibiting factors in the medical equipment cooling market is the initial cost and maintenance expenses associated with advanced cooling systems. Most healthcare institutions in low- and middle-income economies cannot afford the state-of-the-art infrastructure, which hinders market penetration.

Manufacturers face technical challenges in integrating cooling systems into small or portable medical equipment. The problem of compatibility with older models of equipment, as well as the requirement for a customized retrofit, frequently adds costs and extends the installation schedule.

The rigorous regulatory requirements for medical-grade materials, particularly in terms of noise emissions, environmental safety, and fluid management, may hinder the possibility of rapid product approvals and prolong the time-to-market. The issues of refrigerant emission and sustainability demands necessitate significant R&D expenditure to develop compliant yet efficient alternatives.

The market also reacts to disruptions in the global supply chain, which become especially apparent in cases of geopolitical conflicts or pandemics that can affect the availability of components and the continuity of production. A combination of these can slow down short-term growth and lead to the development of more modular, cheaper, and cooling technologies.

Country-Wise Outlook

U.S. Market Driven by Interventional Surge and Outpatient Procedure Shift

The United States continues to lead in the vascular closure devices market, supported by the large number of interventional cardiology and radiology procedures. More than 1.3 million cardiac catheterizations are performed yearly, necessitating the use of VCD in hospitals and ambulatory surgical centers due to the need to provide efficient, safe, and rapid post-procedural hemostasis.

There is a significant trend toward same-day discharge of PCI patients in the U.S., highlighting the importance of suture-based and collagen plug devices in shortening the time-to-ambulation. The ability to integrate with EHR systems allows for the improvement of all aspects of tracking patient outcomes, and the FDA approval of extravascular devices is broadening competitive relationships. Value-based care models also incentivize low complication rates, which is also driving up demand.

Germany’s Precision and Safety Focus Propels VCD Innovation

Germany dominates the European market due to its well-organized system of cardiovascular care and the introduction of new closure methods early. With a high number of elderly people and good reimbursement coverage of minimally invasive procedures, VCDs have become common after angiography and TAVI (Transcatheter Aortic Valve Implantation).

Passive approximators and bioresorbable anchors are of great interest to hospitals because they focus on the low rate of complications and efficiency of the procedures. Germany also invests in clinical research, device comparison, and post-market surveillance. AI-based vascular imaging is being incorporated into cath lab processes specifically, and AI is streamlining the closure decision-making process and enhancing outcomes.

Japan Harnesses Tech for Efficient Vascular Access Management

Japan has established a vascular closure ecosystem characterized by high efficiency and technological integration, which is encouraged by the government's health and productivity management program and the Society 5.0 vision. Growing peripheral interventions in the country, especially among diabetic and aging populations, are among the factors fueling the demand for precision-engineered VCDs.

Real-time imaging and robotic-assisted interventions help hospitals adopt devices that produce minimal trauma to the vessels and enable quicker recovery of the patients. Japan prefers bio-absorbable extravascular devices, which are sustainable according to its interests. Digital health (procedural analytics, predictive modeling, etc.) is being integrated continuously to guarantee the steady monitoring of performance and the adoption of evidence-based closure protocols.

Country Wise Insights

Countries	CAGR (2025 to 35)
United States	5.3%
Germany	5.7%
Japan	6.4%

Category-Wise Analysis

Active Approximators Lead Next-Gen Vascular Closure with Speed and Precision

Active approximators are a technologically advanced category of vascular closure devices (VCD) market, which are developed to deliver fast and effective hemostasis via mechanically deployed closure. In contrast to passive solutions, these devices actively place sutures, clips, or sealing agents to close the arterial puncture site, thereby enhancing patient turnaround times and decreasing post-procedural complications. They are increasingly notable in sophisticated and risk-prone procedures where rapidness and precision are essential, particularly in catheterization laboratories and hybrid OR suites. The demand for active closure systems with built-in safety features is expected to increase steadily as interventional procedures continue to become more complex.

Femoral Access Remains Central to High-Risk and Large-Bore Vascular Interventions

Femoral access still prevails in the setting of large-bore devices or structural heart procedures despite the rising use of radial access. It is still the access of choice for more complicated interventions like transcatheter aortic valve replacement (TAVR), endovascular aneurysm repair (EVAR) and high-ends coronary interventions. Femoral access vascular closure technologies are needed to reduce access-site complications to assure earlier ambulation and discharge. Also, the regulatory aid and clinical experience with femoral-driven techniques make this segment up-to-date, particularly in territories with well-developed cardiovascular systems.

Interventional Cardiology Fuels Demand for Rapid and Reliable Closure Solutions

Interventional cardiology is the major consumer of vascular closure devices due to the high volume of percutaneous coronary interventions (PCIs), diagnostic angiographies, and structural heart procedures. Such procedures need effective arterial closure to facilitate patient safety and maximize cath lab throughput. The closure devices in this industry have to be responsive to sheath sizes, anticoagulation standard practices, and time-dependent environments.

Competitive Analysis

The increasing degree of competition in the vascular closure device market, driven by the innovation of new closure technologies, the adoption of minimally invasive procedures, and enhanced patient recovery, is a major factor in the vascular closure device market. Manufacturers are focusing on product differentiation through the use of new materials, including bioresorbable polymers and non-collagen-based solutions, which aim to minimize the risk of complications and promote vascular healing. Strategic relationships between hospitals and interventional cardiology centers enable companies to ensure procedural volumes and increase clinical evidence that supports their devices.

Regulatory approvals and positive reimbursement policies in developed markets act as barriers to entry for new players, as well as a differentiator for those that can offer better safety profiles. In addition, firms are geographically proliferating through regional collaboration and local production in response to the pressures of cost-effectiveness, particularly in emerging economies.

The technology perspective closeness systems integrated with real-time imaging, as well as an easier mechanism of deployment, is a major battleground. The players are also putting money on training physicians and procedural support programs in order to increase device preference. In general, competitiveness in the marketplace is focused on safety, ease of use, speed of procedure, and control of cost, whereby innovation and integration of services become the core of long-term advantage.

Key players in the vascular closure devices industry include Erumo Corporation, Advanced Vascular Dynamics, Abbott Laboratories, Cardiva Medical Inc., Morris Innovative Inc., Transluminal Technologies, Teleflex Incorporated, Merit Medical Systems Inc., Medas USA, Vygon Company, and other players.

Recent Development

• In August 2024, Haemonetics announced the full market release of its VASCADE MVP® XL mid-bore venous closure system. This device features a larger disc and 58% more collagen than its predecessor, offering robust closure for procedures requiring 10- 12F sheaths, such as cryoablation and left atrial appendage closure, enhancing hemostasis and patient outcomes.
• In July 2024, Cordis received FDA premarket approval for its MYNX CONTROL™ VENOUS Vascular Closure Device, designed for procedures with access sites from 6F to 12F. The device employs an extravascular sealant that expands upon contact with blood, providing secure closure without leaving intravascular components, thus minimizing complications.

Methodology and Industry Tracking Approach

The global vascular closure devices market report by Fact.MR integrates feedback from 13,000 stakeholders across 36 countries, with a minimum of 330 respondents per market. Sixty-four percent were end users or manufacturers, and 36% were professionals, including surgeons, researchers, and regulatory consultants. Data collected between June 2024 and May 2025 captured trends in demand, innovation, investments, risks, and unmet clinical needs across the value chain.

Regional market shares and demographic profiles were used to weight responses. The vascular closure devices market study reviewed over 290 validated sources, including academic journals, patents, regulatory filings, and financial reports. Advanced techniques, such as regression analysis, ensured data accuracy.

Initiated in 2018, Fact.MR’s research has closely tracked advancements in closure systems, patient recovery trends, and product performance, making this report an essential guide for strategic stakeholders.

Segmentation of Vascular Closure Devices Market

• By Type :

  • Active Approximators
  • Passive Approximators
  • External Hemostatic Devices

• By Access :

  • Femoral
  • Radial

• By Procedure :

  • Interventional Cardiology
  • Interventional Radiology/Vascular Surgeries

• By Region :

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa